Non-invasive diagnostic method for interstitial cystitis and bladder cancer
AssigneePromega Corporation
InventorsMary Haak-Frendscho, Angela J. Okragly, Andrew L. Niles, Ricardo Saban
Life of this patent
Estimating the term…
Abstract
Disclosed is a method of diagnosing or monitoring interstitial cystitis or bladder cancer in a mammal. The method comprises analyzing urine of the mammal for the concentration of a urine-soluble protein selected from the group consisting of neurotrophin-3, nerve growth factor, glial cell line-derived neurotrophic factor, tryptase, and combinations thereof.
Claims25
A method of diagnosing or monitoring bladder cancer in a mammal comprising determining concentration of a urine-soluble protein selected from the group consisting of neurotrophin-3, glial cell line-derived neurotrophic factor, tryptase, and combinations thereof in urine from the mammal and from a control population of mammals with no history of bladder cancer;
- and then comparing the concentrations from the mammal with corresponding concentrations from the control population, wherein elevated levels of neurotrophin-3, glial cell line-derived neurotrophic factor, or tryptase in the mammal as compared to the control population is indicative of bladder cancer in the mammal.
A non-invasive method of diagnosing or monitoring bladder cancer in a human subject comprising:
- (a) securing a urine sample from the human subject and from a control population of humans with no history of bladder cancer;
- and then
- (b) determining the presence and concentration in the urine sample from the human subject and from the control population of humans of a urine-soluble protein selected from the group consisting of neurotrophin-3, glial cell line-derived neurotrophic factor, tryptase, and combinations thereof;
- and then comparing the concentrations from the human subject with corresponding concentrations from the control population, wherein elevated levels of neurotrophin-3, glial cell line-derived neurotrophic factor, or tryptase in the human subject as compared to the control population is indicative of bladder cancer in the human subject.
A method of diagnosing or monitoring bladder cancer in a human subject comprising:
- (a) securing a urine sample from the human subject and from a control population of humans with no history of bladder cancer;
- and then
- (b) acidifying the urine samples from the human subject and from the control population to a pH of about 3.0 or less and then neutralizing the urine samples;
- and then
- (c) determining concentration in the urine samples from the human subject and from the control population of a urine-soluble protein selected from the group consisting of neurotrophin-3, glial cell line-derived neurotrophic factor, tryptase, and combinations thereof using a corresponding double antibody-sandwich enzyme-linked immunosorbent assay specific for the urine-soluble protein being analyzed;
- and then comparing the concentrations from the human subject with corresponding concentrations from the control population, wherein elevated levels of neurotrophin-3, glial cell line-derived neurotrophic factor, or tryptase in the human subject as compared to the control population is indicative of bladder cancer in the human subject.
A method of diagnosing or monitoring interstitial cystitis in a mammal comprising determining concentration of a urine-soluble protein selected from the group consisting of neurotrophin-3, glial cell line-derived neurotrophic factor, and combinations thereof in urine from the mammal and from a control population of mammals with no history of interstitial cystitis;
- and then comparing the concentrations from the mammal with corresponding concentrations from the control population, wherein elevated levels of neurotrophin-3 or glial cell line-derived neurotrophic factor in the mammal as compared to the control population is indicative of interstitial cystitis in the mammal.
A non-invasive method of diagnosing or monitoring interstitial cystitis in a human subject comprising:
- (a) securing a urine sample from the human subject and from a control population of humans with no history of interstitial cystitis;
- and then
- (b) determining the presence and concentration in the urine sample from the human subject and from the control population of humans of a urine-soluble protein selected from the group consisting of neurotrophin-3, glial cell line-derived neurotrophic factor, and combinations thereof;
- and then comparing the concentrations from the human subject with corresponding concentrations from the control population, wherein elevated levels of neurotrophin-3 or glial cell line-derived neurotrophic factor in the human subject as compared to the control population is indicative of interstitial cystitis or bladder cancer in the human subject.
A method of diagnosing or monitoring interstitial cystitis in a human subject comprising:
- (a) securing a urine sample from the human subject and from a control population of humans with no history of interstitial cystitis;
- and then
- (b) acidifying the urine samples from the human subject and from the control population to a pH of about 3.0 or less and then neutralizing the urine samples;
- and then
- (c) determining concentration in the urine samples from the human subject and from the control population of a urine-soluble protein selected from the group consisting of neurotrophin-3, glial cell line-derived neurotrophic factor, and combinations thereof using a corresponding double antibody-sandwich enzyme-linked immunosorbent assay specific for the urine-soluble protein being analyzed;
- and then comparing the concentrations from the human subject with corresponding concentrations from the control population, wherein elevated levels of neurotrophin-3 or glial cell line-derived neurotrophic factor in the human subject as compared to the control population is indicative of interstitial cystitis in the human subject.
Dependencies are inferred from the claim text.